Skip to main content
PCSA
NASDAQ Life Sciences

Major Investor Increases Stake in Processa Pharmaceuticals with $200K Purchase

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.087
Mkt Cap
$4.728M
52W Low
$2.03
52W High
$19.635
52W Position info
2.8% above low
Off High info
89% below high
Rel. Volume
Market data snapshot near publication time

PCSA is trading near its 52-week low of $2.03 (2.8% above the low).

Summary

A 10% owner, The Chiliz Group Ltd, invested an additional $200,000 in Processa Pharmaceuticals, increasing its beneficial ownership to 13.0% of outstanding shares.


Key Events · Ownership and Investor Activity · PCSA

  • Significant Share Purchase

    The Chiliz Group Ltd (formerly HX Entertainment Ltd) acquired 86,956 shares of common stock for $200,000 on February 13, 2026.

  • Increased Ownership Stake

    This purchase increases The Chiliz Group's beneficial ownership to 305,644 shares, representing 13.0% of Processa Pharmaceuticals' outstanding common stock.

  • Investment at Premium to Current Market

    The shares were acquired at $2.30 per share, which was above the current market price of $2.0867 and near the 52-week low at the time of the transaction, indicating investor conviction.


Analysis · PCSA · Life Sciences

The Chiliz Group Ltd, a significant 10% owner, increased its stake in Processa Pharmaceuticals by purchasing an additional 86,956 shares for $200,000. This transaction, executed at $2.30 per share on February 13, 2026, demonstrates continued confidence in the company, especially as the purchase price was above the stock's current trading level and near its 52-week low at the time of the transaction. This follows a previous substantial investment in August 2025 and reinforces the investor's strategic interest, despite the recent news on February 19, 2026, regarding the expiration of a binding term sheet for PCS12852.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PCSA was trading at $2.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $2.03 to $19.63. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PCSA - Latest Insights

PCSA
Nov 13, 2026, 5:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.86
Real-time Price: $1.55 info
Change: -$0.310 (-17%) info
Market Cap: $4.365M info
PCSA
Nov 05, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.85
Real-time Price: $1.55 info
Change: -$0.300 (-16%) info
Market Cap: $4.365M info
PCSA
Oct 29, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.95
Real-time Price: $1.55 info
Change: -$0.400 (-21%) info
Market Cap: $4.365M info
PCSA
Oct 29, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.89
Real-time Price: $1.55 info
Change: -$0.340 (-18%) info
Market Cap: $4.365M info
PCSA
Oct 09, 2026, 4:03 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.55 info
Change: +$0.080 (+5%) info
Market Cap: $4.365M info